PERSPECTIVE THERAPEUTICS, INC. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PERSPECTIVE THERAPEUTICS, INC. stock issued during period, value, conversion of convertible securities for fiscal 2018 was $3.00K.
- PERSPECTIVE THERAPEUTICS, INC. stock issued during period, value, conversion of convertible securities for fiscal 2015 was $100.00K, a 98.57% decline from fiscal 2014.
- PERSPECTIVE THERAPEUTICS, INC. stock issued during period, value, conversion of convertible securities for fiscal 2014 was $7.01M, a 384170.74% increase from fiscal 2013.
- PERSPECTIVE THERAPEUTICS, INC. stock issued during period, value, conversion of convertible securities for fiscal 2013 was $1.82K, a 99.78% decline from fiscal 2012.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2018-06-30 | $3.00K 10-K · filed 2020-09-25 | |
| 2015-06-30 | $100.00K 10-K · filed 2017-09-28 | |
| 2014-06-30 | $7.01M 10-K · filed 2016-09-09 | |
| 2013-06-30 | $1.82K 10-K · filed 2015-09-14 | |
| 2012-06-30 | $834.80K 10-K · filed 2013-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |